Altimmune to Attend Upcoming Investor Conferences

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Aug 25 2025

0mins

Source: Globenewswire

Company Overview: Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases.
Upcoming Conferences: The company will participate in several investor conferences, including the Wells Fargo Healthcare Conference on September 5, H.C. Wainwright Global Investment Conference on September 9, and Morgan Stanley Global Healthcare Conference on September 10, 2025.
Webcast Availability: Fireside chats at the H.C. Wainwright and Morgan Stanley conferences will be webcasted and accessible through the Events section of the Altimmune website.
Lead Product Candidate: Altimmune's lead product candidate is pemvidutide, aimed at treating conditions such as MASH, Alcohol Use Disorder, Alcohol-Associated Liver Disease, and obesity.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Let AI Trade for You

Auto Trading Task on NVDA?

Get Started Free